Rectal cancer: Adjuvant therapy and new directions

Kevin P. McMullen, Charles Matthews, A. William Blackstock

Research output: Contribution to journalArticle

Abstract

Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalReviews on Recent Clinical Trials
Volume2
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Rectal Neoplasms
Colonic Neoplasms
Radiation
Patient Selection
Therapeutics
Survival Rate
Drug Therapy
Direction compound
Neoplasms

Keywords

  • Abdominoperineal resection (APR)
  • Adjuvant radiotherapy
  • Flourouracil (5 FU)
  • Postoperative Chemoradiation
  • Total Mesorectal Excision (TME)

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Rectal cancer : Adjuvant therapy and new directions. / McMullen, Kevin P.; Matthews, Charles; Blackstock, A. William.

In: Reviews on Recent Clinical Trials, Vol. 2, No. 1, 01.2007, p. 27-32.

Research output: Contribution to journalArticle

McMullen, Kevin P. ; Matthews, Charles ; Blackstock, A. William. / Rectal cancer : Adjuvant therapy and new directions. In: Reviews on Recent Clinical Trials. 2007 ; Vol. 2, No. 1. pp. 27-32.
@article{f39062f0d46d48baaeabb80c049f6a14,
title = "Rectal cancer: Adjuvant therapy and new directions",
abstract = "Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.",
keywords = "Abdominoperineal resection (APR), Adjuvant radiotherapy, Flourouracil (5 FU), Postoperative Chemoradiation, Total Mesorectal Excision (TME)",
author = "McMullen, {Kevin P.} and Charles Matthews and Blackstock, {A. William}",
year = "2007",
month = "1",
doi = "10.2174/157488707779318071",
language = "English (US)",
volume = "2",
pages = "27--32",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Rectal cancer

T2 - Adjuvant therapy and new directions

AU - McMullen, Kevin P.

AU - Matthews, Charles

AU - Blackstock, A. William

PY - 2007/1

Y1 - 2007/1

N2 - Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.

AB - Cancers of the colon and rectum are a leading cause of cancer-related death in the United States and worldwide. The 5-year survival rates, in general, have improved over time for patients with colon cancer due to evolving preventative strategies, improved screening techniques and the recent development of more effective therapeutic agents. Unfortunately, the treatment for patients with locally advanced rectal cancer remains less studied. This review will highlight recently reported trials evaluating pre-operative versus post-operative treatment strategies. A discussion of ongoing trials incorporating conventional chemotherapy and radiation will be included as well as trials planned or ongoing that incorporate radiation and the targeted agents. Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit.

KW - Abdominoperineal resection (APR)

KW - Adjuvant radiotherapy

KW - Flourouracil (5 FU)

KW - Postoperative Chemoradiation

KW - Total Mesorectal Excision (TME)

UR - http://www.scopus.com/inward/record.url?scp=34248204718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248204718&partnerID=8YFLogxK

U2 - 10.2174/157488707779318071

DO - 10.2174/157488707779318071

M3 - Article

C2 - 18473985

AN - SCOPUS:34248204718

VL - 2

SP - 27

EP - 32

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 1

ER -